Debio 025: Phase IIa data

Debiopharm reported data from a double-blind, placebo-controlled Phase IIa trial in 90 treatment-naïve HCV patients comparing 600 or 1,000 mg/day of Debio 025 plus Pegasys pegylated interferon alfa-2...